Disease Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
0.100 GeneticVariation BEFREE Three SNPs showed a main association with advanced prostate cancer risk after multiple testing correction: catalase (CAT) rs511895, prostaglandin-endoperoxide synthase 2 (PTGS2) rs5275, and xeroderma pigmentosum group C (XPC) rs2228001. 29697282 2019
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
0.100 GeneticVariation BEFREE To quantitatively elucidate the genetic impact of the <i>XPC</i> rs2228000 and rs2228001 polymorphisms on the response to platinum-based chemotherapy, the present meta-analysis was conducted. 31190883 2019
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
0.100 GeneticVariation BEFREE The present study has genotyped 334 subjects from North Indian population for xeroderma pigmentosum complementation Group C (XPC) rs2228001A>C, XPC rs77907221 polyadenylate (PAT) deletion/insertion (D/I), xeroderma pigmentosum complementation Group D - rs13181A>C, and xeroderma pigmentosum complementation Type G rs17655 G>C polymorphisms with polymerase chain reaction (PCR)-restriction-fragment length polymorphism or allele-specific PCR methods. 29893334 2018
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
0.100 GeneticVariation BEFREE In the second part we selected 2 common single nucleotide polymorphisms within genes involved in NER (Xeroderma pigmentosum group C (XPC) Lys939Gln, Xeroderma pigmentosum group D (XPD) Lys751Gln) to determine the relation between them and CRC risk. 29793654 2018
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
0.100 GeneticVariation BEFREE A total of 7 XPC tagging SNPs (tag-SNPs) were selected from the International HapMap Project Databases (rs2228001A/C, rs2470353G/C, rs2228000C/T, rs3731114C/G, rs3729587G/C, rs2607775C/G and rs3731055G/A) and were genotyped in 205 patients with PC and 230 non-cancer control subjects using a SNaPshot assay. 30344718 2018
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
0.100 GeneticVariation BEFREE The purpose of this study was to evaluate the relationship between single-nucleo­tide polymorphism (SNP) rs2228001 in xeroderma pigmentosum group C (XPC), SNP rs4073 in interleukin 8 (IL8), and SNP rs2279744 in mouse double minute 2 (MDM2) homolog gene with PCa susceptibility. 26135929 2015
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
0.100 GeneticVariation BEFREE Interestingly, we found significant correlation between Lys939Gln genotypes and XPC mRNA expression for Asian populations as well. 24375193 2014
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
0.100 GeneticVariation BEFREE This meta-analysis based on current evidences suggested that the XPC polymorphisms (Lys939Gln, Val499Arg, and PAT-/+) did not contribute to gastric cancer risk. 24886180 2014
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
0.100 GeneticVariation BEFREE A meta-analysis was performed to examine the association between XPC Lys939Gln polymorphism and susceptibility to bladder cancer (BC). 23269608 2013
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
0.100 GeneticVariation BEFREE Our meta-analysis suggested that the XPC Lys939Gln polymorphism contributed to the risk of urinary bladder cancer. 23819639 2013
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
0.100 GeneticVariation BEFREE The current data suggested that XPC Ala499Val and Lys939Gln polymorphisms may contribute to the identification of patients with increased risk for BC. 22519360 2012
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
0.100 GeneticVariation BEFREE The distributions of XPC Lys939Gln genotypes differed significantly between the response group (complete + partial responses) and the non-response group (stable + progressive disease; P = 0.022). 22166526 2010
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
0.100 GeneticVariation BEFREE To investigate the association between two Xeroderma pigmentosum group C polymorphism (XPC Lys939Gln and insertion/deletion PAT -/+ in intron 9) and bladder cancer (BC) susceptibility. 19924443 2010
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
0.100 GeneticVariation BEFREE These analyses suggest that XPC Lys(939)Gln, PAT+/- and Ala(499)Val likely contribute to susceptibility to cancers. 18771913 2008
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
0.100 GeneticVariation BEFREE We evaluated the association of two common non-synonymous polymorphisms in XPC (Ala499Val and Lys939Gln) with breast cancer risk in the Long Island Breast Cancer Study Project (LIBCSP), a population-based case-control study. 18053706 2008
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
0.100 GeneticVariation BEFREE The polyAT, intronic IVS11-6 and Lys939Gln XPC polymorphisms are not associated with transitional cell carcinoma of the bladder. 15886698 2005